PAULSON & CO. INC. — Quarter-over-Quarter 13F Allocation Shifts Q1 2026
In Q1 2026, PAULSON & CO. INC. initiated 1 new position, increased allocation to 2 existing positions, trimmed 1 position, and exited 1 position entirely. The fund's 13F equity book declined from $3.26B to $3.11B (-4.6% QoQ) . All deltas are sourced from sequential SEC Form 13F-HR filings; share-count changes reflect explicit trading activity, while weight changes can also include price movement. This page lists every position change reported — the portfolio overview shows a summary of the top shifts.
Net Portfolio Value Change
- $3.26BPrior quarter
- $3.11BCurrent quarter
- $-0.15BNet delta
- -4.6%% change
New Position Initiations Q1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Allocation Weight | History |
|---|---|---|---|
| AMICUS THERAPEUTIC | FOLD | 0.02% | History → |
Largest Allocation Increases Q1 2026
Largest portfolio-weight increases in existing positions. Share-count delta is shown separately so price-only re-weighting can be distinguished from active adds.
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| THRYV HLDGS INC | THRY | +-0.06% | +94.24% | History → |
| INTERNATIONAL TOWER HILL MIN | THM | +3.36% | +41.76% | History → |
Largest Allocation Reductions Q1 2026
Largest portfolio-weight decreases in existing positions (positions kept open at a lower allocation).
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| MADRIGAL PHARMACEUTICALS INC | MDGL | -7.06% | -18.47% | History → |
Exited Positions Q1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| SOLSTICE ADVANCED MATLS INC | SOLS | 2.08% |
Methodology & FAQ
How PAULSON & CO. INC. Quarterly Changes Are Computed
Each row above is computed by joining the most recent 13F-HR filing for PAULSON & CO. INC. against the immediately preceding quarterly filing for the same fund. Portfolio weights are normalized to exclude listed options for comparability. A complete description of the methodology — including how confidential treatment filings are handled and why share count rather than weight is the cleaner trading signal — is documented in the Methodology.
Which positions did PAULSON & CO. INC. initiate in Q1 2026?
PAULSON & CO. INC. established 1 new position in Q1 2026: AMICUS THERAPEUTIC (FOLD, 0.02%).
Which existing positions saw the largest allocation increases for PAULSON & CO. INC. in Q1 2026?
The largest portfolio-weight increases in existing positions were: THRYV HLDGS INC (THRY, +-0.06% weight, +94.24% shares), INTERNATIONAL TOWER HILL MIN (THM, +3.36% weight, +41.76% shares).
Which positions did PAULSON & CO. INC. fully exit in Q1 2026?
PAULSON & CO. INC. fully exited 1 position in Q1 2026: SOLSTICE ADVANCED MATLS INC (SOLS, last-reported weight 2.08%).
Which existing positions saw the largest allocation reductions for PAULSON & CO. INC. in Q1 2026?
The largest portfolio-weight reductions in positions kept open were: MADRIGAL PHARMACEUTICALS INC (MDGL, -7.06% weight, -18.47% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity.